CB-25 is a stable analog of anandamide (AEA) and Δ9-tetrahydrocannabinol (THC). It exhibits high affinity for the central cannabinoid (CB1) and peripheral cannabinoid (CB2) receptors with Ki values of 5.2 and 13 nM, respectively. CB-25 behaves as an inverse agonist for the CB1 receptor as assessed in a cyclic AMP (cAMP) functional assay.
